Colorectal Cancer | Specialty

Dr. Lwin on Patient Selection for LEAP-005 Study in CRC, Biliary Tract Cancer, and More

January 20th 2021

Zarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.

Dr. Lenz on the Promise of ctDNA in the mCRC Treatment Paradigm

January 20th 2021

Heinz-Josef Lenz, MD, FACP, discusses the promise of circulating tumor DNA in colorectal cancer.

Dr. Pandalai on Outcomes With Adjuvant HIPEC in CRC

January 19th 2021

Prakash Pandalai, MD, discusses outcomes with adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.

Dr. Raghav on the Role of Molecular Profiling in Treatment Selection in mCRC

January 18th 2021

Kanwal Raghav, MBBS, MD, discusses the role of molecular profiling in treatment selection for patients with metastatic colorectal cancer.

TAS-102 Plus Bevacizumab Improves OS in mCRC Ineligible for Intensive Therapy

January 17th 2021

January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.

Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC

January 16th 2021

January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

Lenvatinib and Pembrolizumab Combination Safe, Effective For Multiple Gastrointestinal Cancer Types

January 15th 2021

The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers

Health-Related Quality of Life Scores in Young CRC Survivors Are Low and Require Targeted Intervention

January 15th 2021

January 15, 2021 - As the incidence of colorectal cancer in patients under 50-years-old increases, overall health-related quality of life among younger survivors is poorer, with social and functional well-being suffering more as treatment duration grows longer.

Anlotinib Induces PFS Benefit in RAS/BRAF Wildtype+ mCRC

January 15th 2021

January 15, 2021 - Anlotinib, a multitarget kinase inhibitor, was found to significantly improve progression-free survival with a manageable safety profile when used in Chinese patients with refractory metastatic colorectal cancer.

Dr. Mai on Barriers of Genetic Testing in CRC

January 13th 2021

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

x